Study 55 of 57Semaglutide literaturebiorxiv-preprint · Observational

Side effects of lower dose compounded semaglutide paired with a behavioral management program: A real-world retrospective study

Lower doses of compounded semaglutide may lead to fewer side effects compared to higher doses in the first 16 weeks of treatment.

Read at biorxiv-preprint Add to compare

Where it sits

this study against the rest of the semaglutide corpus

Preclinical

Observational · this one

Open-label

Randomised

Reviews

Summary and findings

This study evaluated side effects of low versus standard doses of compounded semaglutide in a real-world setting over 16 weeks. It compared 7,682 users of the standard dose program to 2,877 users of the low dose program. The findings indicated lower odds of gastrointestinal and any side effects in the low dose group.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →

34% lower relative odds of reporting GI side effects by week 16, p=0.001, n=2,481 per group.

Abstract

The authors’ words, as biorxiv-preprint supplied them

<h4>Objective</h4> Evaluate differences in side effects between a low and standard dose compounded semaglutide paired with a behavioral companion in the first 16 weeks of treatment using a real-world, retrospective cohort. <h4>Methods</h4> Side effects were compared between the low dose protocol (Noom Microdose GLP-1 Rx Program; NMGP, up to 0.6mg/weekly compounded semaglutide) and Noom’s standard dose of compounded semaglutide (Noom GLP-1 Rx Program; NGP, up to 1.2mg/weekly). Users were propensity score matched on side effect rate in the first 8 weeks when dosing protocols were identical, and longitudinal side effect trajectories were compared via logistic regression. Analyses were conducted on a second cohort with additional matched baseline characteristics. <h4>Results</h4> The full sample included 7,682 NGP and 2,877 NMGP users. NMGP users had 34% lower and 29% lower relative odds of reporting GI side effects ( p =0.001) and any side effects ( p =0.001) by week 16, respectively (n=2,481 per group). Results of the second cohort demonstrated 38% lower odds of any side effect by week 16 among NMGP users (n=958 per group, p =0.019). <h4>Conclusions</h4> Lower doses of compounded semaglutide alongside a behavioral companion are associated with fewer side effects in the first 16 weeks compared to a higher dose program.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Semaglutide corpus

DSemaglutide and Suicidality in Adults with Overweight or Obesity: A Bayesian Meta-Analysis of Randomized Trialsbiorxiv-preprint · Completed suicide: pooled OR 1.56 (95% CrI 0.55–4.67), P(OR > 1) = 80.6%, n=17,086 semaglutide vs 15,304 placebo.review BWeight loss with a lower dose compounded semaglutide and behavioral weight management program: A real-world matched retrospective cohort studybiorxiv-preprint · At 16 weeks, NMGP users lost 8.3% of their baseline weight.Human BA study on risk factors for the progression from T2DM to end-stage renal disease based on Mendelian randomization and logistic regression analysis.Renal failure · 2026 · n=875 · AUC of the logistic regression-based nomogram was 0.88 (95% CI: 0.85-0.91).Human BFeasibility and acceptability of an everyday patient-centered discussion model for primary care: An exploratory, single-center study in the VA primary care setting.PEC innovation · 2026 · n=23 · Mean SDM-Q-9 score was 90.9 out of 100.Human BOral Health Outcomes with GLP1 Receptor Agonists Compared with Other Metabolic Interventionsbiorxiv-preprint · 2026 · 8.69% of GLP-1 users developed at least one newly documented oral-health condition.Human COral Semaglutide Preserves Islet of Langerhans Structure and Cellular Integrity in a Type 2 Diabetes Mellitus Rat Model: Histological, Immunohistochemical, and Biochemical Studybiorxiv-preprint · 2026 · P < 0.05 for islet size, β-cell mass, and insulin immunoreactivity.Animal